Searchable online Canadian database of health product adverse reactions

You can read the descriptive news story or go directly to the database.

Novartis GIST Registry

Help Novartis Oncology collect information from doctors on the diagnosis and management of GIST via doctor participation in a GIST Registry. Print a brochure about the GIST Registry to bring to your doctor.

Sarcoma Awareness Week

The Sarcoma Alliance urges all sarcoma patients to participate in Sarcoma Awareness Week June 11-18, 2006 by doing something on the local level to gain attention for sarcoma. Arthur Beckert prepared a list of possible activites you could do in your community: download the list here. For more information contact

Phase I Clinical Trial of IPI-504

-- Novel Treatment Paradigm Has Potential to Address Resistance to Current Targeted Therapies -- CAMBRIDGE, Mass., Jan. 10 /PRNewswire/ -- Infinity Pharmaceuticals, Inc.today announced the initiation of a second Phase I clinical trial of IPI-504,the company's Heat Shock Protein 90 (Hsp90) inhibitor and lead investigationalanti-cancer agent. This study, part of

4-year follow-up of Gleevec

At the ASCO Gastrointestinal Cancer Symposium held in late January, 2006, Dr. Charles Blanke presented a poster detailing 4-year follow-up results of the patients in the first randomized Phase II clinical trial of Gleevec for treatment of GIST, known as the B2222 trial. These patients represent the longest ongoing data

Biology of Gastrointestinal Stromal Tumors — Corless et al. 22 (18): 3813 — Journal of Clinical Oncology

Christopher L. Corless, Jonathan A. Fletcher, Michael C. Heinrich From the Oregon Health & Science University Cancer Institute, Department of Pathology, and Division of Hematology and Oncology, Oregon Health & Science University and Veterans Affairs Medical Center, Portland, OR; and Department of Pathology, Brigham & Women’s Hospital, Boston, MA </font

Study finds new designer drug is potent treatment for chronic myelogenous leukemia

Hybrid targeted therapy effective in treating Gleevec-resistant disease BOSTON–Using rational drug design strategies, investigators atDana-Farber Cancer Institute and Novartis Pharmaceuticals in Basel,Switzerland have created a targeted therapy for chronic myelogenousleukemia (CML) that may ultimately be more effective than Gleevec ®, thecurrent frontline treatment. The researchers report in the Februaryissue of

FDA Works to Speed the Advent of New, More Effective Personalized Medicines

As part of an agency-wide initiative to speed development of new medical products through the science of pharmacogenomics, the Food and Drug Administration (FDA) today issued a final guidance titled “Pharmacogenomic Data Submissions.” Pharmacogenomics allows health care providers to identify sources of an individual’s profile of drug response and predict

Consensus meeting for the management of gastrointestinal stromal tumors: report of the GIST Consensus Conference of 3/2004, under the auspices of ESMO

Below is an informal summary of a consensus summary on GIST treatment by an international group of GIST experts. The consensus conference to develop this guideline was sponsored by the European Society of Medical Oncology (ESMO) with a grant from Novartis. A meeting was held in March 2004 among 41

Molecular Testing in Patients with Rare Cancer Predicts Response to Gleevec

PORTLAND, Ore. – Patients with gastrointestinal stromal tumors (GIST) who have a particular genetic mutation are more likely to respond to Gleevec (imatinib) than those without the mutation, according to OHSU study results showcased at the 2005 annual meeting of the American Society of Clinical Oncology (ASCO). The results confirm